Clarity Pharmaceuticals bags FDA fast track designation for prostate cancer candidate 67Cu-SAR-bisPSMA
Clarity Pharmaceuticals has achieved a major regulatory milestone with the United States Food and Drug Administration (FDA) granting Fast Track Designation to 67Cu-SAR-bisPSMA, a targeted ... Read More
Xencor stock skyrockets 26% overnight after breakthrough in cancer research
Xencor, Inc., a clinical-stage biopharmaceutical company specializing in engineered antibodies for cancer treatment, saw its stock rise by 26% to $20.39 on Monday following substantial ... Read More
Novartis completes $2.1bn acquisition of Endocyte to boost cancer treatment capabilities
Swiss pharmaceutical giant Novartis has officially closed its $2.1 billion acquisition of US-based biopharma company Endocyte, solidifying its position as a leader in radiopharmaceuticals for ... Read More